Title: Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies.

Keywords: Trace amine-associated receptors (TAARs); murine and human TAAR1 agonists; phenyl biguanide derivatives; benzyl biguanide derivatives.

Corresponding Author: Dr. Michele Tonelli, PhD
Corresponding Author's Institution: University of Genoa
First Author: Michele Tonelli, PhD
Order of Authors: Michele Tonelli, PhD; Stefano Espinoza, PhD; Raul Gainetdinov, PhD; Elena Cichero, PhD

Abstract: Trace amines (TAs) are endogenous neuromodulators that play a functional role in the synaptic transmission within central nervous system (CNS), targeting trace amine-associated receptors (TAARs). Starting from our previous computational studies on TAAR1 and TAAR5 interactions with the unselective ligand 3-iodothyronamine (T1AM), we rationally designed and synthesized a new series of biguanide-based compounds that were evaluated in functional activity at murine and human TAAR1 and murine TAAR5 receptors. Among them, phenyl (BIG2, BIG4, BIG8 and BIG22) or benzyl (BIG10-BIG16) biguanides were found to be selective murine and human TAAR1 agonists with potencies in nanomolar or low micromolar range, respectively. In particular, compounds BIG2 and BIG12-BIG14 were the most promising and they could be considered valuable lead compounds worthy of further investigations.

In addition to the interest for developing more effective human TAAR1 ligands, the disclosed here potent murine TAAR1 agonists could offer suitable tools for studying the pharmacology of TAAR1 receptor.
Dear Professor Supuran,

on behalf of all co-authors, I am pleased to submit the enclosed manuscript entitled “Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies” for publication, as an article, on European Journal of Medicinal Chemistry.

Starting from our previous computational studies on TAAR1 and TAAR5 interactions with the unselective ligand 3-iodothyronamine (T1AM), we rationally designed and synthesized a new series of biguanide-based compounds that were evaluated in functional activity at murine and human TAAR1 and murine TAAR5 receptors. The phenyl and benzyl biguanide derivatives, bearing lipophilic substituents, emerged as two interesting subsets and were of particular interest combining the high activity with more accessible synthetic routs. In fact phenyl (BIG2, BIG4, BIG8 and BIG22) or benzyl (BIG10-BIG16) biguanides were found to be selective murine and human TAAR1 agonists with potencies in nanomolar or low micromolar range, respectively. Notably, compounds BIG2 and BIG12-BIG14 were the most promising and they could be considered valuable lead compounds worthy of further investigations.

In addition to the interest for developing more effective human TAAR1 ligands, the disclosed here potent murine TAAR1 agonists could offer suitable tools for studying the pharmacology of TAAR1 receptor.

Thank you very much and kindest regards.

Yours sincerely,

Michele Tonelli

*Corresponding author.
Phone: +39 010 3538867. E-mail: michele.tonelli@unige.it
Graphical abstract

Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies.
Michele Tonelli\textsuperscript{a,*}, Stefano Espinoza\textsuperscript{b}, Raul R. Gainetdinov\textsuperscript{c,d}, Elena Cichero\textsuperscript{a,*}
Highlights

- Computationally-driven studies guided for the synthesis of selective TAAR1 agonists
- In this study we prepared linear and cyclic biguanide-based compounds
- Phenyl and benzyl biguanides were found active at murine and human TAAR1 receptors
- Docking studies revealed a bridge role of biguanide moiety in stabilizing H-bonds
Novel biguanide-based derivatives scouted as TAAR1 agonists: synthesis, biological evaluation, ADME prediction and molecular docking studies.
Michele Tonelli\textsuperscript{a,*}, Stefano Espinoza\textsuperscript{b}, Raul R. Gainetdinov\textsuperscript{c,d}, Elena Cichero\textsuperscript{a,*}

\textsuperscript{a}Department of Pharmacy, University of Genoa, Viale Benedetto XV n. 3, 16132, Genoa, Italy
\textsuperscript{b}Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Genoa, Italy
\textsuperscript{c}Institute of Translational Biomedicine, St. Petersburg State University, 199034, St. Petersburg, Russia
\textsuperscript{d}Skolkovo Institute of Science and Technology, Skolkovo, 143025, Moscow Region, Russia

\textsuperscript{*}To whom correspondence should be addressed:
Dr. Michele Tonelli: tel: +390103538867; fax: +390103538399. E-mail: michele.tonelli@unige.it.
Dr. Elena Cichero: tel: +390103538370; fax: +39 0103538399; E-mail: cichero@unige.it
Abstract
Trace amines (TAs) are endogenous neuromodulators that play a functional role in the synaptic transmission within central nervous system (CNS), targeting trace amine-associated receptors (TAARs). Starting from our previous computational studies on TAAR1 and TAAR5 interactions with the unselective ligand 3-iodothyronamine (T1AM), we rationally designed and synthesized a new series of biguanide-based compounds that were evaluated in functional activity at murine and human TAAR1 and murine TAAR5 receptors. Among them, phenyl (BIG2, BIG4, BIG8 and BIG22) or benzyl (BIG10-BIG16) biguanides were found to be selective murine and human TAAR1 agonists with potencies in nanomolar or low micromolar range, respectively. In particular, compounds BIG2 and BIG12-BIG14 were the most promising and they could be considered valuable lead compounds worthy of further investigations.

In addition to the interest for developing more effective human TAAR1 ligands, the disclosed here potent murine TAAR1 agonists could offer suitable tools for studying the pharmacology of TAAR1 receptor.

Keywords: Trace amine-associated receptors (TAARs), murine and human TAAR1 agonists, phenyl biguanide derivatives, benzyl biguanide derivatives.

1. Introduction
Trace amine-associated receptors (TAARs) belong to the family of G-protein coupled receptors (GPCR), whose first identified member TAAR1 was cloned and deorphanized at the beginning of the twenty-first century by two research groups, working independently [1,2]. Indeed, multiple TAARs genes were identified, which included 9 genes in humans (TAAR1, TAAR2, TAAR5, TAAR6, TAAR8, TAAR9 with TAAR3, TAAR4 and TAAR7 being pseudogenes), 9 in chimpanzees (including 6 pseudogenes), 19 in rats (including 2 pseudogenes), and 16 in mice (including 1 pseudogene). Among them, TAAR1 was the only member initially identified as responsive to a class of biogenic compounds called trace amines (TAs) [3]. TAs, such as tyramines, β-phenylethylamine (β-PEA), octopamines, tryptamine, 3-iodothyronamine (T1AM) and synephrine are found in mammals at low levels
in multiple tissues, both in the periphery and in the brain, but their precise physiological functions have still to be clarified [4].

TAs were described playing a key role as major neurotransmitters in invertebrates, as shown by octopamine that was the most related counterpart of norepinephrine [5,6]. Initially, it was proposed that the main effect determined by TAs was related to sympathomimetic-like actions, and that in any case TAs could behave as neuromodulators of the dopaminergic or adrenergic systems [4]. Accordingly, TAAR1 proved to be expressed in the nigrostriatal and mesolimbic dopaminergic pathways and a number of pharmacological advances pointed out a prominent functional inter-regulation between TAAR1 and dopamine system [7]. As an overall effect, TAAR1 modulate the dopaminergic transmission working as a fine-tuning mechanism [8,9]. Dysfunction of TAs signaling was historically associated to a consistent number of psychiatric diseases believed to be related to alterations in monoaminergic balance [10].

The first receptor types to be investigated was TAAR1, which were expressed in a variety of tissues including brain, stomach, kidney, lung and intestine, but not in the olfactory epithelium (OE). On the contrary, with the exception of TAAR1, all the other TAARs proved to be mainly present in small areas of olfactory sensory neurons (OSNs) in the OE [11]. However, more recent studies revealed biological functions of TAAR2 and TAAR5 receptors beyond olfaction, revealing their presence also at the immune system level and at CNS [12-14]. Indeed, TAAR2 and TAAR5 co-expression with TAAR1 at high levels within human blood leukocytes was recently described, while new evidence pointed out to the presence of TAAR5 in brain regions, such as the ventromedial hypothalamus (VMH) and the amygdala [15].

Despite of these recent findings potentially guiding for innovative therapies in neurons and immune cell system modulation, nowadays the most relevant advances regarding TAARs were based on studies focused on TAAR1 receptor. Growing appreciation of the potential of TAAR1-based pharmacology led to the search for related ligands, mostly due to numerous evidences pointing out that targeting TAAR1 could lead to novel approaches for the treatment of several disorders, such as schizophrenia, depression, attention deficit hyperactivity disorder, Parkinson’s disease, addiction and metabolic diseases [16-21].

Up to now, different classes of chemical entities were studied and recognized as TAAR1 ligands, including specific molecules screened and developed as TAAR1 agonists [22] and also known dopaminergic, adrenergic and serotonergic ligands, but at expense of selectivity. On the other hand, only two antagonists were described, including a benzamide-based
derivative, namely RO5212773 (EPPTB) [23], and a phenoxyethylamine-based compound [24]. Conversely, only a few number of TAs were assayed and then identified as TAAR2 or TAAR5 ligands, being T1AM the most investigated.

T1AM was revealed as a promiscuous TAARs ligand, being able to bind unselectively at least to TAAR1, TAAR2 and TAAR5. In particular, it was found as potent murine TAAR1 agonist (mTAAR1 EC₅₀ = 189 nM) [25], lowering in potency at the human orthologue receptor (hTAAR1 EC₅₀ = 1690 nM) [26].

Based on these information, the most critical concerns in the development of effective TAAR1 ligands were firstly selectivity within the TAARs family and further monoamines-directed towards GPCRs, as well as species-specificity variation, as observed around TAs [27].

Recent synthetic efforts were aimed to optimize the efficacy of newly TAAR1 agonists, relying on rational drug design strategies including development of endogenous ligand analogues [25], computationally-driven virtual screenings [24,28] and SOSA approach (Selective Optimization of Side Activities) [29].

In the first case, a series of thyronamine analogues were synthesized leading to compounds whose potency profile toward the mTAAR1 falls in the low micromolar range, while by virtual screening approaches Lam and co-workers identified the drug Guanabenz [30] and closely related benzylidene aminoguanidine derivatives [28], exhibiting activity as mTAAR1 agonists (Fig. 1).

![Fig. 1. Chemical structures and functional data of thyronamine analogues and of Guanabenz and related derivatives, studied as mTAAR1 ligands. β-PEA was positive control.](image-url)
More recent SOSA studies performed starting from compounds active towards the adrenoreceptor system, such as the 2-adrenoreceptor partial agonist S18616, allowed to derive new series of TAAR1 compounds endowed with improved efficacy also at the hTAAR1 receptor. The typical aromatic ring and basic moiety of S18616 was maintained, modifying the linker region by opening the central six-membered ring. As shown in Fig. 2, following this strategy a number of promising 2-aminooxazolines were developed, acting as hTAAR1 agonists or partial agonists.

![Chemical structures](image)

**Fig. 2.** Chemical structures and functional data of 2-aminooxazolines as hTAAR1 ligands [29].

In this context, we started our work exploring TAARs and related ligands applying homology modelling calculations. The computational approach allowed us to build and compare murine and human TAARs models, including TAAR1, TAAR2 and TAAR5 receptors, pointing out any structural feature at their putative binding site that could be involved in ligand recognition. All the models were compared on the basis of docking calculations of the promiscuous ligand 3-iodothyronamine (T1AM), revealing a pattern of key contacts probably responsible for the potency, selectivity profile and species-specificity of TAAR1 ligands [31,32].

In particular, our results promoted the design of small more rigid or planar scaffold bearing proper H-bonding features, rather than the 3-iodothyronamine structure, for the
development of more potent and selective TAAR1 ligands. Based on these results, we proceeded with the synthesis of a new series of compounds exhibiting a biguanide moiety as a rigid basic feature, replacing the flexible ethylamine displayed by T_{1}AM.

The biguanide system is considered an important scaffold endowed with several biological activities: besides the well known properties of currently used therapeutics, as the antidiabetic metformin, the antimalarial proguanil and the antiseptic chlorhexidine, this framework was associated to serotoninergic antagonists [33], antiviral [34-36], anti-H_{2} [37,38] and anticancer agents [39,40].

In the present work, we searched for linear (BIG1-BIG23) and cyclic (Cyc1, Cyc2) biguanide-based derivatives as novel TAAR chemotypes (Fig. 3), in virtue of their chemical tractability (synthetically accessible and low cost). We have also explored the potential activity of two 2,4-diaminopyrimidines, pyrimethamine (Cyc3) and trimethoprim (Cyc4), as planar analogues of 4,6-diamino-1,2-dihydrotriazines Cyc1 and CyC2 (Fig. 3).
It is worth noting that the pheyl(benzyl) biguanide system calls back the chemical structure of the previously discussed drug Guanabenz [28] and of the related analogues (Fig. 1).

Thus, twenty-seven compounds have been evaluated in functional activity at murine and human TAAR1 (m/hTAAR1) and murine TAAR5 (mTAAR5) receptors.

These data were accompanied by a thorough in silico evaluation of the pharmacokinetic and toxicity properties of the most potent derivatives here disclosed, with the aim at gaining preliminary information concerning their potentially drug-like profile.
These combined studies led to the identification of promising series of molecules to be further optimized as much more effective hTAAR1 ligands, but also as mTAAR1 agonists, as suitable tools for exploring the TAARs pharmacology.

2. Results and discussion

2.1. Chemistry

Most of the investigated compounds have already been reported in the literature: BIG2 [41], BIG3 [42], BIG5 [43] BIG6 [44], BIG7 [45], BIG8 and BIG9 [46], BIG10 [42], BIG11, BIG12, BIG14 and BIG15 [47].

Compounds BIG13, BIG16 and BIG17 were known as free base or nitrate/dipicrate salts [44], while in our synthetic conditions they crystallized directly from the reaction mixture as pure hydrochlorides, thus their experimental properties have been reported herein. BIG21 [48], moroxydine BIG23 [44]. Syntheses of compounds Cyc1 and Cyc2 were achieved by 3-component syntheses [43].

The novel biguanide compounds BIG13 and BIG16-BIG20 were synthesized by fusing at 180-200°C for 1 h an equimolar mixture of the proper cycloalkylamine hydrochloride or substituted benzylamine hydrochloride and dicyandiamide (Scheme 1).

In addition to the experimental data, the formation of linear biguanide derivatives was confirmed by pink copper complexes with freshly cuprammonium sulphate solution, in contrast to cyclic biguanides (Cyc1 and Cyc2).

\[
\begin{align*}
\text{R} & \text{Cl} + \text{NC} \leftrightarrow \text{NH} \leftrightarrow \text{NH}_2 & \rightarrow & \text{R} \text{NH}_2 \text{NH}_2 \text{Cl} \\
& \text{BIG13, BIG16-BIG18} \\
\text{X} & \text{NH}_2 \text{Cl} + \text{NC} \leftrightarrow \text{NH} \leftrightarrow \text{NH}_2 & \rightarrow & \text{X} \text{NH}_2 \text{NH}_2 \text{Cl} \\
& \text{BIG19, BIG20}
\end{align*}
\]

**Scheme 1.** Reagents and conditions: a) 180-200°C, 1 h.
All new compounds showed excellent analytical and spectroscopic data, in good agreement with their structures (see Experimental Part). The chemical structure of the nonplanar biguanide core has been fully elucidated [49,50] stating, as predominant tautomer, the one without hydrogens at the bridging nitrogens, thus permitting a high degree of conjugation (as for BIG1-BIG22). In the $^1$H NMR spectra of the corresponding benzyl biguanide hydrochloride salts, the NH protons give rise to a singlet near $\delta$ 9 to 10 and NH$_2$ groups yield signals in the range $\delta$ 7 to 8 [49].

2.2. Molecular docking studies

During the last years, our interest in TAAR pharmacology driven our computational efforts to the development of thorough homology modelling studies around TAAR1 and TAAR5 receptors. The models we derived allowed us to compare the receptors topology and to investigate for ligand potency and selectivity issues [31,32]. Our data suggested that the $m$TAAR1 ligand potency trend was highly related to the presence of a proper basic feature linked to an aromatic core, being the compound engaged in a key salt bridge between a protonated amine group and the highly conserved residue D102, together with a number of $\pi-\pi$ stacking and cation-$\pi$ contacts with the surrounding amino acids [32].

Indeed, for TAAR1 as well as for TAAR5, the interaction with a conserved aspartic acid residue proved to be mandatory, as successively confirmed by Reese for the murine TAAR1 receptor [51].

In particular, according to the results we obtained about T$_1$AM, the compound basic moiety was better stabilized at the $m$TAAR1 rather than at the $h$TAAR1 or $m/h$TAAR5, by means of additional H-bonds with surrounding aromatic residues, being these information consistent with the decreasing potency trend of those molecules bearing exclusively a basic feature, moving from the murine to the human species, as described in literature [52].

In addition, the phenolic hydroxyl group of T$_1$AM was in any case H-bonded to the TAAR receptor, while the 3-iodo-phenyl ring showed cation-$\pi$ contacts with a conserved arginine residue [32]. Notably, the 3-iodo-phenyl core occupied a cavity including hydrophobic and flexible residues (such as leucine and isoleucine) in TAAR5, being conversely in proximity of aromatic and much more rigid amino acids in $m$TAAR1 (such as phenylalanine and tyrosine) or smaller residues (such as valine) in $h$TAAR1.
Thus, the selection of smaller or of much more rigid or planar scaffolds bearing proper H-bonding features emerged to be allowed for the design of more effective TAAR1 ligands, also endowed with an improved selectivity profile with respect to TAAR5.

Based on these results, we deemed interesting to evaluated the possibility to apply a molecular simplification on the chemical structure of T1AM, leading to a new series of compounds lacking of the phenolic portion (which was involved H-bonds within both the TAAR1 and TAAR5 receptors impairing selectivity) and exhibiting a biguanide moiety, instead of the ethylamine chain, as a rigid basic feature.

Docking studies performed at the murine TAAR1 receptor revealed a quite comparable binding mode shared by most of the BIG compounds here proposed. In particular, the most promising para-substituted phenyl derivatives BIG4 and BIG8 were characterized by a net of H-bonds brought by the biguanide moiety and the neighbouring S79, D102, S182 and Y291 residues, moving the phenyl core toward N283 and P280, as displayed by the 3-iodophenyl ring of T1AM (Fig. 4).

![Docking mode of T1AM and BIG compounds](image)

**Fig. 4.** Docking mode of T1AM (C atom; green) and of compounds BIG4 (C atom; deep magenta) and BIG8 (C atom; dark cyan) at the murine TAAR1 binding site. The most important residues are labelled.
It should be noticed that BIG4 and BIG8 didn’t interact with the binding crevice surrounding the T1AM phenolic substituent, therefore displaying a lower potency profile with respect to the reference compound.

While the aforementioned para-substituted derivatives were unable to mimic the T1AM phenolic ring, the ortho-substituted BIG2 adequately moved the chlorine substituent toward the aforementioned region, achieving a better efficacy with respect to the related analogues (Fig. 5).

**Fig. 5.** Docking mode of T1AM (C atom; green) and of compound BIG2 (C atom; yellow) at the murine TAAR1 binding site. The most important residues are labelled.

The orto- or para-substituted benzyl derivatives BIG11 and BIG13 arranged the biguanide moiety and the aromatic ring following a highly comparable positioning to that of the phenyl analogue BIG2, detecting the same pattern of H-bonds and therefore displaying a similar potency profile (Fig. 1S). Even in these cases, the protein region delimited by T83, R86, C87 and D284 interacting with T1AM was unoccupied by the newly synthesized compounds.

Notably, the meta- substitution and also the meta- and para- di-substitution resulted to be particularly effective for the mTAAR1 activity, allowing the benzyl ring to lay within the
receptor binding site in a much more similar way if compared with T1AM. Indeed, the 3-chlorobenzyl-based BIG12 and the 3,4-dichlorobenzyl analogue BIG14 appeared to quite overlap the docking mode observed for T1AM through their aromatic ring (Fig. 2S and Fig. 6). In addition, this kind of positioning allowed the biguanide moiety to be engaged in multiple H-bonds contacts with D102 and also to behave as a bridge interacting with D284, leading to a highly stabilized protein-ligand complex, as we discussed in our previous works.

![Fig. 6. Docking mode of T1AM (C atom; green) and of compound BIG14 (C atom; pink) at the murine TAAR1 binding site. The most important residues are labelled.](image)

Notably, these results were in accordance with the biological data described in the following section, giving an interesting explanation of the improved TAAR1 agonist activity of BIG12 and BIG14 if compared with T1AM.

Molecular docking studies within the human TAAR1 receptor were conducted using S18616 [29] as reference compound, being characterized by a high potency toward the biological target (hTAAR1 EC50= 15 nM) and also by a rigid spiro-anellated structure that allow to limit its possible conformational variability within the receptor binding site and therefore to derive much more reliable information.
The primary amine group of the ligand was engaged in H-bonds with the key residue D103 and Y294 while the aromatic portion was placed in a receptor cavity delimited by R83, S183, N286, D287 (Fig. 3S). In particular, S18616 was stabilized within the hTAAR1 binding site by cation-π contacts with R83 and also due to a H-bond acceptor-like behaviour played by the chlorine atom with respect to the N286 side-chain.

Regarding the newly synthesized biguanide-based compounds, the driving force moving the ligand positioning within the receptor cavity was highly related to the possibility to contact N286, as we previously discussed for S18616. Indeed, the phenyl derivatives BIG2, BIG4 and BIG8 placed the aromatic core in proximity of that of the reference compound, being only the orto-substituted BIG2 able to weakly mimic the S18616 chlorine (Fig. 7).

**Fig. 7.** Docking mode of S18616 (C atom; light green) and of compounds BIG2 (C atom; orange) and BIG4 (C atom; dark grey) at the human TAAR1 binding site. The most important residues are labelled.
Accordingly, **BIG2** was the only phenyl derivative endowed with an acceptable *h*TAAR1 agonist activity, being on the contrary the related 4-chlorophenyl (**BIG4**) and 4-tolyl (**BIG8**) analogues inactive.

Concerning the biguanide moiety, it appeared to be H-bonded to H99, D103 and Y294, being a good bioisostere of the **S18616** aminooxazoline ring.

The introduction of a benzyl moiety instead of the phenyl ring led to much more promising *h*TAAR1 ligands (**BIG11-16**), whose putative binding mode included H-bonds with S80, D103 and Y294, similarly to the corresponding pattern of contacts shown by the **S18616** oxazoline cycle (Fig. 8). The overall arrangement of the benzyl group allowed moving the aromatic ring near I290, F185, F267, detecting Van der Waals and \(\pi-\pi\) stacking interactions. Among these derivatives, the *para*-substitution with an electron-rich atom improved the ligand potency probably reinforcing any possible (weak) polar contact with N286. On the other hand, all the compounds here proposed partially covered the pattern of interactions detected by the bulky spiro-anellated core of **S18616**. Consequently, they displayed in any case moderately weak or poor bonds with the receptor crevice including N286, exhibiting lower potency values than the reference compound. Nevertheless, especially this series of derivatives could be further optimized as *h*TAAR1 ligands thanks to a proper selection of substituents to be placed at the benzyl *para* position or modifying the benzyl core with a bulkier aromatic/heteroaromatic systems.
Fig. 8. Docking mode of S18616 (C atom; light green) and of compound BIG14 (C atom; deep magenta) at the human TAAR1 binding site. The most important residues are labelled.

2.3. ADME in silico evaluation

Nowadays, the computational prediction of descriptors representing absorption, distribution, metabolism, excretion and toxicity properties (ADMET) are considered useful in silico tools, accelerating the lead compound discovery process [53].

Thus, for the active BIG compounds we evaluated a series of ADMET properties, also taking into account the related parameters calculated for two potent hTAAR1 ligands described in literature, RO5256390 and RO5263397, whose favourable pharmacokinetic profile was experimentally determined [29]. Briefly, RO5256390 and RO5263397 were characterized by an acceptable human hepatocyte clearance and inhibitory activity of the cytochrome isoforms, displaying an in vitro safety profile performed by (negative) AMES/MNT test and hERG IC₅₀ evaluation. Based on these data the two compounds were retained as development candidates as partial TAAR1 agonists. Notably, in our compound series the plasmonicidal drug proguanil (BIG22) was also included: as known, it is slowly but adequately absorbed per os, it is partially metabolized by CYP2C subfamily to the active
metabolite cycloguanil and is excreted in the urine. It is considered well-tolerated and safe [54].

In this work, for the aforementioned compounds, the logarithmic ratio of the octanol-water partitioning coefficient (cLogP), extent of blood-brain barrier permeation (LogBB), rate of passive diffusion-permeability (LogPS), human intestinal absorption (HIA), volume of distribution (Vd), the role played by plasmatic protein binding (%PPB) and by the ligand affinity toward the human serum albumin (LogK\text{HSA}) were taken into account (Table 1).

The putative metabolism and toxicity profiles of any compound was determined on the basis of a number of descriptors such as the compound potential behaviour as P-glycoprotein inhibitor or substrate, the ability to interact with the endocrine system and to act as cytochrome P450 3A4 inhibitor or substrate, the median lethal dose (LD\text{50}) related to oral administration (see Table 2).

Table 1. Calculated ADMET descriptors related to absorption and distribution properties.

<table>
<thead>
<tr>
<th>Comp.</th>
<th>cLogP</th>
<th>LogBB\text{a}</th>
<th>LogPS\text{b}</th>
<th>HIA (%)\text{c}</th>
<th>Vd (l/kg)\text{d}</th>
<th>%PPB</th>
<th>LogK\text{HSA}</th>
<th>%F (oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIG2</td>
<td>1.36</td>
<td>0.14</td>
<td>-3.5</td>
<td>48</td>
<td>3.2</td>
<td>30</td>
<td>3.14</td>
<td>28.8</td>
</tr>
<tr>
<td>BIG4</td>
<td>1.22</td>
<td>0.08</td>
<td>-3.3</td>
<td>53</td>
<td>3.5</td>
<td>42</td>
<td>2.99</td>
<td>32.3</td>
</tr>
<tr>
<td>BIG8</td>
<td>0.94</td>
<td>0.08</td>
<td>-3.7</td>
<td>43</td>
<td>3.5</td>
<td>27</td>
<td>2.55</td>
<td>25.1</td>
</tr>
<tr>
<td>BIG10</td>
<td>-0.17</td>
<td>-0.02</td>
<td>-4.6</td>
<td>39</td>
<td>3.3</td>
<td>12</td>
<td>2.41</td>
<td>22.2</td>
</tr>
<tr>
<td>BIG11</td>
<td>0.88</td>
<td>-0.03</td>
<td>-4.2</td>
<td>35</td>
<td>3.5</td>
<td>27</td>
<td>2.74</td>
<td>19.5</td>
</tr>
<tr>
<td>BIG12</td>
<td>0.88</td>
<td>-0.03</td>
<td>-4.2</td>
<td>35</td>
<td>3.5</td>
<td>27</td>
<td>2.74</td>
<td>19.5</td>
</tr>
<tr>
<td>BIG13</td>
<td>0.88</td>
<td>-0.03</td>
<td>-4.2</td>
<td>35</td>
<td>3.5</td>
<td>27</td>
<td>2.74</td>
<td>19.5</td>
</tr>
<tr>
<td>BIG14</td>
<td>0.84</td>
<td>-0.11</td>
<td>-4.2</td>
<td>35</td>
<td>3.5</td>
<td>27</td>
<td>2.74</td>
<td>19.5</td>
</tr>
<tr>
<td>BIG15</td>
<td>-0.16</td>
<td>-0.01</td>
<td>-4.6</td>
<td>38</td>
<td>3.1</td>
<td>11</td>
<td>2.42</td>
<td>18.3</td>
</tr>
<tr>
<td>BIG16</td>
<td>0.80</td>
<td>-0.02</td>
<td>-4.3</td>
<td>33</td>
<td>3.7</td>
<td>23</td>
<td>2.60</td>
<td>19.5</td>
</tr>
<tr>
<td>BIG22</td>
<td>2.32</td>
<td>0.38</td>
<td>-3.1</td>
<td>75</td>
<td>5.4</td>
<td>52</td>
<td>3.19</td>
<td>18.3</td>
</tr>
<tr>
<td>RO5256390</td>
<td>2.62</td>
<td>0.46</td>
<td>-2.0</td>
<td>100</td>
<td>4.0</td>
<td>63</td>
<td>3.19</td>
<td>19.5</td>
</tr>
<tr>
<td>RO5263397</td>
<td>1.92</td>
<td>0.35</td>
<td>-2.0</td>
<td>100</td>
<td>2.4</td>
<td>28</td>
<td>3.12</td>
<td>99.0</td>
</tr>
</tbody>
</table>

\text{\textsuperscript{a}}Extent of brain penetration based on ratio of total drug concentrations in tissue and plasma at steady-state conditions; \text{\textsuperscript{b}}Rate of brain penetration. PS represents Permeability-Surface area product and is derived from the kinetic equation of capillary transport; \text{\textsuperscript{c}}HIA represents the human intestinal absorption, expressed as percentage of the molecule able to pass through the intestinal membrane; \text{\textsuperscript{d}}prediction of Volume of Distribution (Vd) of the compound in the body.

As shown in Table 1, all the compounds with the exception of BIG10 and BIG15 were characterized by an adequate lipophilicity, being the calculated cLogP below 5 (Lipinski rules) and that of BIG2 comparable with the one of RO5263397. Among the most active compounds, BIG2 was endowed with the ability to be partially adsorbed at the human
intestinal membrane (HIA = 48%). Notably, all the derivatives show poor blood-brain barrier (BBB) permeation for passive diffusion, showing LogBB and/or LogPS values falling sometimes out of the recommended ranges (0<LogBB<1.5; -3<LogPS<-1). Nevertheless, all of them were predicted to penetrate the BBB by means of active transport carrier.

The calculated volume of distribution values and also the potential binding to the plasmatic proteins fall in the allowed ranges and in any case within those displayed by RO5256390 and RO5263397. In particular BIG2 and BIG14 were characterized by the most similar Vd and %PPB values.

According to an overall analysis of the descriptors listed in Table 2, none of the compounds here proposed should be substrate of the P-glycoprotein, or be involved in genotoxicity events such as binding with the endocrine system. Indeed, all the derivatives were characterized by acceptable LogRBA values, being lower than -3 within high reliability indices.

Furthermore, none of them proved to inhibit the cytochrome P450 3A4, being on the contrary substrate for the enzyme at lower values than that displayed by RO5256390 and RO5263397.

Notably, all of them exhibited a favourable safety profile, being the estimated LD$_{50}$ in the range of 640-1400 mg/kg for mouse after oral administration, being in any case higher than those calculated for the two development candidate RO5256390 and RO5263397.
Table 2. Calculated ADMET descriptors related to metabolism, excretion and toxicity properties.

<table>
<thead>
<tr>
<th>Comp.</th>
<th>P-glycoprotein</th>
<th>Endocrine System Disruptiona</th>
<th>CYP3A4</th>
<th>LD₅₀b (mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Inhib. (R.I.≥ 0.40)</td>
<td>LogRBA&gt; -3 (R.I.≥ 0.50)</td>
<td>LogRBA&gt; 0 (R.I.≥ 0.80)</td>
<td>Inhib. (R.I.≥ 0.50)</td>
</tr>
<tr>
<td>BIG2</td>
<td>not</td>
<td>0.12</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG4</td>
<td>not</td>
<td>0.06</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG8</td>
<td>not</td>
<td>0.06</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG10</td>
<td>not</td>
<td>0.01</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG11</td>
<td>not</td>
<td>0.03</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG12</td>
<td>not</td>
<td>0.03</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG13</td>
<td>not</td>
<td>0.03</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG14</td>
<td>not</td>
<td>0.05</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG15</td>
<td>not</td>
<td>0.01</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG16</td>
<td>not</td>
<td>0.04</td>
<td>0.00</td>
<td>not</td>
</tr>
<tr>
<td>BIG22</td>
<td>not</td>
<td>0.06</td>
<td>0.01</td>
<td>not</td>
</tr>
<tr>
<td>RO5256390</td>
<td>not</td>
<td>0.05</td>
<td>0.01</td>
<td>not</td>
</tr>
<tr>
<td>RO5263397</td>
<td>not</td>
<td>0.03</td>
<td>0.01</td>
<td>not</td>
</tr>
</tbody>
</table>

aRBA represents the relative binding affinity with respect to that of estradiol. Compounds showing LogRBA> 0 are classified as strong estrogen binders, while those showing LogRBA< -3 are considered as non-binders.
bAcute toxicity (LD₅₀) for mouse after oral administration (RI: reliability index. Borderline-allowed values for reliability parameter are ≥0.3, the most predictive fall in the range 0.50-1.0); cMRDD represents the maximum recommended daily dose.

3. Biological evaluation

3.1. Structure-activity relationships of biguanide derivatives on m/hTAAR1.

Twenty-two linear biguanides (BIG1-BIG22), two 4,6-diamino-1,2-dihydropyrimidines (Cyc1-Cyc2) and two 2,4-diaminopyrimidines (Cyc3-Cyc4) considered in this work were evaluated for functional activity at m/hTAAR1 and mTAAR5 receptors (Table 3). Unfortunately, the absence of a potent compound stimulating the human form prevents setting up a related pharmacological protocol about hTAAR5.

The activity of the compounds was measured using HEK-293 cells transfected with m/hTAAR1 or mTAAR5, or empty vector as control, and a cAMP BRET biosensor. β-PEA was used as positive control for agonism. In the initial screening phase, all the compounds were tested at 10 μM either for agonistic or antagonistic activity. Then for the compounds that were active, a dose-response experiment was performed using concentrations ranging from 10 nM to 100 μM in order to calculate their corresponding EC₅₀ values. The Emax value for the functional activity data at TAARs describes the degree of functional activity.
compared to 100% for the natural ligand and full agonist β-PEA. All the compounds displayed an Emax>85% at m/hTAAR1, thus they were regarded as full agonist.

The species-specificity ratio (SSR) of mTAAR1 versus hTAAR1 is determined by dividing the hTAAR1 EC50 value by the mTAAR1 EC50 value (Table 3).
Table 3. Functional activity at m/hTAAR1 and mTAAR5 receptors for compounds BIG1-BIG23 and Cyclic1-Cyclic4.$^{a,b}$

<table>
<thead>
<tr>
<th>Compds</th>
<th>R</th>
<th>R$_1$</th>
<th>EC$_{50}$ (nM)</th>
<th>Species-Specificity Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H</td>
<td>410</td>
<td>1000</td>
<td>2.44</td>
</tr>
<tr>
<td>BIG2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIG4</td>
<td>Cl-H</td>
<td>H</td>
<td>2100</td>
<td>&gt;10000</td>
</tr>
<tr>
<td>BIG8</td>
<td>H$_2$C-</td>
<td>H</td>
<td>1700</td>
<td>&gt;10000</td>
</tr>
<tr>
<td>BIG10</td>
<td>OMe-CH$_2$-</td>
<td>H</td>
<td>780</td>
<td>&gt;10000</td>
</tr>
<tr>
<td>BIG11</td>
<td>OMe-CH$_2$-</td>
<td>H</td>
<td>410</td>
<td>3000</td>
</tr>
<tr>
<td>BIG12</td>
<td>Cl-CH$_2$-</td>
<td>H</td>
<td>97</td>
<td>7000</td>
</tr>
<tr>
<td>BIG13</td>
<td>Cl-CH$_2$-</td>
<td>H</td>
<td>780</td>
<td>1800</td>
</tr>
<tr>
<td>BIG14</td>
<td>Cl-CH$_2$-</td>
<td>H</td>
<td>36</td>
<td>1200</td>
</tr>
<tr>
<td>BIG15</td>
<td>OMe-CH$_2$-</td>
<td>H</td>
<td>540</td>
<td>1600</td>
</tr>
<tr>
<td>BIG16</td>
<td>Br-CH$_2$-</td>
<td>H</td>
<td>1800</td>
<td>4900</td>
</tr>
<tr>
<td>BIG22</td>
<td>Cl-Cl</td>
<td>iPr</td>
<td>5400</td>
<td>&gt;10000</td>
</tr>
</tbody>
</table>

$^a$ Only the compounds active as m/hTAAR1 ligands are listed. $^b$ All the compounds were shown inactive as mTAAR5 ligands up to the highest concentration tested (EC$_{50}$ > 10 μM).
The active compounds were found selective only for TAAR1 subtype, leaving unaffected mTAAR5. Activity is displayed only by phenyl (BIG2, BIG4, BIG8 and BIG22) or benzyl (BIG10-BIG16) biguanides, while dihydrotriazine and pyrimidine scaffolds were responsible for lacking (losing) of any activities against the investigated targets. Eleven out of twenty-seven compounds exhibited mTAAR1 agonistic behavior with EC\(_{50}\) values in the range 36-5400 nM, while 64% of them was also able to target hTAAR1 with low micromolar potency.

All the active compounds on both m/hTAAR1 subtypes bore lipophilic substituents (Cl, F, Br, CH\(_3\)) on the aromatic ring, with the electron-withdrawing chlorine atom as the best substitution, instead polar groups (OCH\(_3\), NO\(_2\)) resulted detrimental (BIG7, BIG9, BIG17 and BIG18).

In particular within the phenyl biguanides subset, the most potent mTAAR1 agonist was the 1-(ortho-chlorophenyl)biguanide (BIG2) with an EC\(_{50}\)= 410 nM, while the corresponding para-Cl (BIG4) and meta-Cl isomers (BIG3) showed a 5-fold decrease or even loss of activity, respectively. In the case of the antimalarial drug proguanil (BIG22), the simultaneous presence of 1-(4-chlorophenyl) ring and the bulky 5-isopropyl group on the biguanide moiety is responsible for a reduction of activity that reached the highest EC\(_{50}\) value equal to 5400 nM. Besides halogens, also the apolar and electron-donor para-CH\(_3\) substituent was permitted, but providing a lower efficacy (BIG8).

In the benzyl biguanides subset, the mono-Cl substitution in meta-position increased the activity at mTAAR1 (BIG12, EC\(_{50}\)= 97 nM), whereas ortho- and para-substitutions were less favorable with a 4-fold (BIG11) or 8-fold (BIG13) decreases of the potency. Having assumed the meta-Cl substituent as the best suited in this subset, firstly the isosteric replacement of chlorine with fluorine or bromine atoms was also explored, however obtaining less effective agonists (BIG15, BIG16) which displayed EC\(_{50}\) values of 540 and 1800 nM, respectively. Indeed, the combination of meta- and para-substitutions with two chlorine atoms led to the most potent tested derivative (BIG14), exhibiting an EC\(_{50}\)= 36 nM.

Concerning the activity at hTAAR1, SARs moved with a slightly different trend compared to mTAAR1: first compound BIG2 was found the only active representative of phenyl biguanide system and the most potent with an EC\(_{50}\)= 1000 nM, whilst the 3,4-dichlorobenzyl derivative BIG14 ranked second for efficacy (EC\(_{50}\)= 1200 nM). Regarding the effect of mono-substitution on the benzyl moiety, the para-Cl group was more tolerated than ortho-Cl and meta-Cl, since compound BIG13 (EC\(_{50}\)= 1800 nM) was 1.7-fold and 3.9-fold more active than BIG11 and BIG12, respectively. Unlike the aforementioned excellent activity at
mTAAR1 of BIG12, for hTAAR1 the meta-Cl substitution was less favorable than meta-Br (BIG16) and, even more, than meta-F (BIG15) ones.

In Table 3 the species-specificity ratio (SSR) values are also listed, in order to highlight species-specific differences influenced by variation of the chemical space on the biguanide skeleton. All the compounds shared a better agonist behavior versus mTAAR1 with respect to hTAAR1 and, in particular, compounds BIG12 and BIG14 displayed the highest SSR values equal to 72.16 and 33.33, respectively.

Compound BIG13, although 21.6-fold and 1.5-fold less active at mTAAR1 and hTAAR1, respectively, than BIG14, possessed the lowest specificity ratio (SSR= 2.31), thus suggesting that the mono-substitution in para-position with a lipophilic group on the benzyl biguanide scaffold was the well-suited, capable of enhancing activity versus hTAAR1.

Finally, concerning the phenyl biguanide subset, only the ortho-substitution on the aromatic ring with a chlorine atom was responsible for a low SSR value comparable to that of BIG14, as shown by the most active hTAAR1 agonist BIG2 (SSR=2.44).

4. Conclusions
Herein we described the discovery of potent and selective m/hTAAR1 agonists, characterized by a biguanide moiety. Notably, the phenyl and benzyl biguanide derivatives, bearing lipophilic substituents, emerged as two interesting subsets and were of particular interest combining the high activity with more accessible synthetic routs. Thus, compounds BIG2 and BIG12-BIG14 were the most promising and they could be considered valuable lead compounds worthy of further investigations. In view of a future chemical optimization, the analysis of the in vitro TAAR1 activity data reported in this work suggested the following observations: a) the importance of a rigid scaffold, such as the biguanide one, to obtain an improved selectivity profile versus TAAR1 with respect to TAAR5; b) a benzyl biguanide scaffold substituted in para-position with lipophilic groups, or replaced by bulkier aromatic or heteroaromatic rings for an improved species-specificity versus hTAAR1; c) a planar phenyl biguanide system substituted in ortho-position with apolar groups, for the design of potent hTAAR1 ligands. In addition to the interest for developing more effective hTAAR1 ligands, nevertheless the here disclosed potent mTAAR1 agonists (BIG14 and BIG12) could offer suitable tools for studying the pharmacology of TAAR1 receptor.

5. Experimental section
5.1. Chemistry
5.1.1. General methods

Chemicals, solvents and commercially available compounds [1-phenylbiguanide hydrochloride (BIG1), 1-(4-chlorophenyl)biguanide hydrochloride (BIG4), proguanil (BIG22), pyrimethamine (Cyc3) and trimethoprim (Cyc4)] were purchased from Sigma-Aldrich (Milan, Italy). Column chromatography (CC): neutral alumina (Al₂O₃), activity 1 (Merck) or silica gel. Mps: Büchi apparatus, uncorrected. ¹H NMR spectra and ¹³C NMR spectra: Varian Gemini-200 spectrometer; CDCl₃ or DMSO-d₆; d in ppm rel. to Me₄Si as internal standard. J in Hz. Elemental analyses were performed on a Carlo Erba EA-1110 CHNS-O instrument in the Microanalysis Laboratory of the Department of Pharmacy of Genoa University. The NMR spectra of compounds BIG13 and BIG16-BIG20 are shown in the Supplementary data. Results of elemental analyses and NMR spectra indicated that the purity of all compounds was ≥95%.

5.1.2. General method for the synthesis of biguanide derivatives

A mixture of proper cycloalkyl- or benzylamine hydrochloride (2.6 mmol) and cyanoguanidine (2.6 mmol) was heated at 180-200°C. The molten mass was maintained at the same temperature for 1 h. After cooling the hard solid residue was dissolved in MeOH and the solution concentrated under vacuum, affording the title monohydrochlorides (cpds. BIG19, BIG20). In the case of benzylbiguanide derivatives (BIG13 and BIG16-BIG18) the monohydrochloride salts were high hygroscopic, thus the residues were directly converted into the more stable dihydrochloride salts with 1N ethanolic solution of HCl.

5.1.3. 1-(4'-Chlorobenzyl)biguanide dihydrochloride (BIG13)

Yield: 69%. Mp 215-218°C (dec.). ¹H NMR (200 MHz, CDCl₃): 4.26-4.63 (m, 2 H, NCH₂-Ar), 7.08-7.80 (m, 8H, 4 ArH and 2NH₂ that exchange with D₂O), 8.57 (br. s, NH₂, exchange with D₂O), 9.28 (br. s, "NH, exchange with D₂O), 9.91 (br. s, "NH, exchange with D₂O). ¹³C NMR (50 MHz, CDCl₃): 157.99, 136.09, 131.59, 130.61, 129.54, 128.69, 128.06, 42.71. Anal. Calcd for C₉H₁₂ClN₅+ 2HCl+ 0.2H₂O: C, 35.77; H, 4.80; N, 23.17. Found: C, 35.84; H, 4.79; N, 23.22.

5.1.4. 1-(3'-Bromobenzyl)biguanide dihydrochloride (BIG16)

Yield: 76%. Mp 221-224°C (dec.). ¹H NMR (200 MHz, CDCl₃): 4.26-4.63 (m, 2 H, NCH₂-Ar), 7.00-7.75 (m, 8H, 4 ArH and 2NH₂ that exchange with D₂O), 8.54 (br. s, NH₂, exchange with D₂O), 9.28 (br. s, "NH, exchange with D₂O), 9.89 (br. s, "NH, exchange with
$^{13}$C NMR (50 MHz, CDCl$_3$): 157.78, 140.05, 129.50, 126.89, 126.00, 121.33, 42.48. Anal. Calcd for C$_9$H$_{12}$BrN$_5$+ 2HCl+ 0.2H$_2$O: C, 31.18; H, 4.19; N, 20.20. Found: C, 31.42; H, 4.35; N, 20.14.

5.1.5. 1-(4'-Methoxybenzyl)biguanide dihydrochloride (BIG17)
Yield: 84%. Mp 200-204°C (dec.). $^1$H NMR (200 MHz, CDCl$_3$): 3.74 (s, 3H, OCH$_3$), 4.23-4.50 (m, 2 H, NCH$_2$-Ar), 6.92 (d, J = 8.4, 2H, ArH), 7.10-7.60 (m, 6H, 2ArH and 2NH$_2$ that exchange with D$_2$O), 8.50 (br. s, NH$_2$, exchange with D$_2$O), 9.20 (br. s, $^1$NH, exchanges with D$_2$O), 9.87 (br. s, $^1$NH, exchange with D$_2$O). $^{13}$C NMR (50 MHz, CDCl$_3$): 158.21, 156.68, 129.15, 128.70, 128.33, 113.46, 54.74, 42.98.

Anal. Calcd for C$_{10}$H$_{15}$N$_5$O$^+$ 2HCl+ 0.2H$_2$O: C, 40.33; H, 5.89; N, 23.52. Found: C, 40.53; H, 5.85; N, 23.57.

5.1.6. 1-(3,4-Dimethoxybenzyl)biguanide dihydrochloride (BIG18)
Yield: 80%. Mp 181-184°C (dec.). $^1$H NMR (200 MHz, CDCl$_3$): 3.73 (s, 6H, 2OCH$_3$), 4.22-4.54 (m, 2 H, NCH$_2$-Ar), 6.73-7.65 (m, 7H, 3 ArH and 2NH$_2$ that exchange with D$_2$O), 8.60 (br. s, NH$_2$, exchange with D$_2$O), 9.30 (br. s, NH$_2$+, exchange with D$_2$O), 9.88 (br. s, NH$_2$+, exchanges with D$_2$O). $^{13}$C NMR (50 MHz, CDCl$_3$): 158.08, 156.80, 148.31, 148.07, 129.11, 120.15, 119.16, 111.88, 55.19, 43.40. Anal. Calcd for C$_{11}$H$_{17}$N$_5$O$_2$+ 2HCl+ 0.25H$_2$O: C, 40.19; H, 5.98; N, 23.52. Found: C, 40.53; H, 5.85; N, 23.57.

5.1.7. 1-Cyclopentylbiguanide hydrochloride (BIG19)
Yield: 78%. Mp 240-241°C. $^1$H NMR (200 MHz, CDCl$_3$): 1.20-2.00 (m, 8 H, 4CH$_2$ cyclopentane), 3.89 (pseudo s, 1 H, CH, cyclopentane), 6.95 (br s, 6 H, 3NH$_2$ exchange with D$_2$O), 7.74 (br s, 1 H, $^1$NH, exchanges with D$_2$O). $^{13}$C NMR (50 MHz, CDCl$_3$): 159.96, 157.79, 51.90, 31.99, 22.78. Anal. Calcd for C$_7$H$_{15}$N$_5$ +HCl: C, 40.87; H, 7.84; N, 34.05. Found: C, 40.88; H, 7.89; N, 33.88.

5.1.8. 1-Cycloheptylbiguanide hydrochloride (BIG20)
Yield: 69%. Mp 198-201°C. $^1$H NMR (200 MHz, CDCl$_3$): 1.04-1.90 (m, 12H, 6CH$_2$ cycloheptane), 3.64 (pseudo s, 1 H, CH, cycloheptane), 6.56-7.20 (m, 6 H, 3NH$_2$ exchange with D$_2$O), 7.55 (br s, 1 H, $^1$NH, exchanges with D$_2$O). $^{13}$C NMR (50 MHz, CDCl$_3$): 162.54, 159.46, 157.17, 50.98, 33.94, 27.32, 22.92. Anal. Calcd for C$_9$H$_{19}$N$_5$ + HCl+ 0.5H$_2$O: C, 44.53; H, 8.72; N, 28.85. Found: C, 44.36; H, 8.75; N, 28.68.
5.2. Molecular modeling studies

The reference ligands T₁AM, S₁8616, RO5256390 and RO5263397 and the most promising BIG compounds were built in silico, parameterized (Gasteiger-Huckel method) and energy minimized within MOE using MMFF94 forcefield [55], taking into account all the possible tautomers.

Molecular docking studies were performed using the previously built mTAAR1 and hTAAR1 homology models, focusing on the binding site we carefully had evaluated around T₁AM [31,25]. Successively, flexible docking studies were applied using the Surflex docking module implemented in Sybyl-X1.0 [56].

Surflex-Dock uses an empirically derived scoring function based on the binding affinities of X-ray protein-ligand complexes. The Surflex-Dock scoring function is a weighted sum of non-linear functions involving van der Waals surface distances between the appropriate pairs of exposed protein and ligand atoms, including hydrophobic, polar, repulsive, entropic and solvation and crash terms represented in terms of a total score conferred to any calculated conformer.

Finally, the stability of the derived protein-ligand complexes was successfully assessed using a short ~1 ps run of molecular dynamics (MD) at constant temperature, followed by an all-atom energy minimization (LowModeMD implemented in MOE software). In this way, an exhaustive conformational analysis of the ligand-receptor binding site complex was explored, as we already explained about other case studies for a preliminary evaluation of the derived docking poses [57,58].

5.3. In silico evaluation of pharmacokinetic properties

The prediction of ADMET properties were performed using the Advanced Chemistry Development (ACD) Percepta platform (www.acdlabs.com).

Any ADMET descriptor was evaluated by Percepta based on training libraries implemented in the software, which include a consistent pool of molecules whose pharmacokinetic and toxicity profiles are experimentally known.


HEK-293 cells were transiently transfected with m/hTAAR1 or mTAAR5 and a cAMP BRET biosensor (EPAC) and then plated in a 96-well plate as described [59]. For time course experiments, the plate was read immediately after the addition of the agonist and for approximately 20 min. All the compounds were tested at the initial concentration of 10 μM.
Then, for active compounds, a dose response was performed in order to calculate the EC$_{50}$ values. All the experiments were conducted in the presence of the phosphodiesterase inhibitor IBMX (Sigma) at the final concentration of 200 μM. Readings were collected using a Tecan Infinite instrument that allows the sequential integration of the signals detected in the 465–505 nm and 515–555 nm windows using filters with the appropriate band-pass and by using iControl software. The acceptor/donor ratio was calculated as previously described [60]. Curve was fitted using a nonlinear regression and one site specific binding with GraphPad Prism 5. Data are representative of 4–6 independent experiments and are expressed as means ± SEM.

Acknowledgments

This work was financially supported by the University of Genova. RRG was supported by the Russian Science Foundation (project N14-25-00065). The Authors would like to thank O. Gagliardo for performing elemental analyses.

Supplementary data

Docking poses of T$_{1}$AM, BIG11 and BIG13 (Fig. 1S), of T$_{1}$AM and BIG12 (Fig. 2S), of S18616 (Fig. 3S) and $^1$H and $^{13}$C NMR spectra of the newly synthesized compounds are reported.

References


30


[56] Sybyl-X 1.0 Tripos Inc 1699 South Hanley Road. St Louis. Missouri. 63144. USA 25


